CliffBio
small molecule

VANTRELA ER

HYDROCODONE BITARTRATE

Loss of exclusivityJuly 2029latest FDA-listed patent expiry
CompanyTEVA BRANDED PHARMACEUTICAL PRODUCTS R AND D INC

Drug detail

Brand nameVANTRELA ER
Active ingredientHYDROCODONE BITARTRATE
Strength60MG
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalJanuary 2017
Marketing statusDISCN

Listed patents

PatentExpiresType
8445018July 2029product
9216176September 2027product
9572803September 2027product

More from TEVA BRANDED PHARMACEUTICAL PRODUCTS R AND D INC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

VANTRELA ER patent cliff — loss of exclusivity July 2029 | CliffBio